Panel MiRNAs Are Potential Diagnostic Markers for Chronic Kidney Diseases: a Systematic Review and Meta-analysis

Overview

Journal BMC Nephrol

Publisher Biomed Central

Specialty Nephrology

Date 2024 Aug 13

PMID 39138396

Authors

Gantsetseg Garmaa

Rita Nagy

Tamas Koi

Uyen Nguyen Do To

Dorottya Gergo

Denes Kleiner

Dezso Csupor

Peter Hegyi

Gabor Kokeny

Affiliations

Soon will be listed here.

Abstract

Background: Accurate detection of kidney damage is key to preventing renal failure, and identifying biomarkers is essential for this purpose. We aimed to assess the accuracy of miRNAs as diagnostic tools for chronic kidney disease (CKD).

Methods: We thoroughly searched five databases (MEDLINE, Web of Science, Embase, Scopus, and CENTRAL) and performed a meta-analysis using R software. We assessed the overall diagnostic potential using the pooled area under the curve (pAUC), sensitivity (SEN), and specificity (SPE) values and the risk of bias by using the QUADAS-2 tool. The study protocol was registered on PROSPERO (CRD42021282785).

Results: We analyzed data from 8351 CKD patients, 2989 healthy individuals, and 4331 people with chronic diseases. Among the single miRNAs, the pooled SEN was 0.82, and the SPE was 0.81 for diabetic nephropathy (DN) vs. diabetes mellitus (DM). The SEN and SPE were 0.91 and 0.89 for DN and healthy controls, respectively. miR-192 was the most frequently reported miRNA in DN patients, with a pAUC of 0.91 and SEN and SPE of 0.89 and 0.89, respectively, compared to those in healthy controls. The panel of miRNAs outperformed the single miRNAs (pAUC of 0.86 vs. 0.79, p < 0.05). The SEN and SPE of the panel miRNAs were 0.89 and 0.73, respectively, for DN vs. DM. In the lupus nephritis (LN) vs. systemic lupus erythematosus (SLE) cohorts, the SEN and SPE were 0.84 and 0.81, respectively. Urinary miRNAs tended to be more effective than blood miRNAs (p = 0.06).

Conclusion: MiRNAs show promise as effective diagnostic markers for CKD. The detection of miRNAs in urine and the use of a panel of miRNAs allows more accurate diagnosis.

Citing Articles

Chronic Kidney Disease Progression-A Challenge.

Maringhini S, Zoccali C Biomedicines. 2024; 12(10).

PMID: 39457516 PMC: 11505431. DOI: 10.3390/biomedicines12102203.

References

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

Sun Y, Peng R, Peng H, Liu H, Wen L, Wu T . miR-451 suppresses the NF-kappaB-mediated proinflammatory molecules expression through inhibiting LMP7 in diabetic nephropathy. Mol Cell Endocrinol. 2016; 433:75-86. DOI: 10.1016/j.mce.2016.06.004. View

Hong Y, Wang J, Zhang L, Sun W, Xu X, Zhang K . Plasma miR-193a-3p can be a potential biomarker for the diagnosis of diabetic nephropathy. Ann Clin Biochem. 2020; 58(2):141-148. DOI: 10.1177/0004563220983851. View

Xiao B, Wang L, Li W, Gong L, Yu T, Zuo Q . Plasma microRNA panel is a novel biomarker for focal segmental glomerulosclerosis and associated with podocyte apoptosis. Cell Death Dis. 2018; 9(5):533. PMC: 5945632. DOI: 10.1038/s41419-018-0569-y. View

Navarro-Quiroz E, Pacheco-Lugo L, Lorenzi H, Diaz-Olmos Y, Almendrales L, Rico E . High-Throughput Sequencing Reveals Circulating miRNAs as Potential Biomarkers of Kidney Damage in Patients with Systemic Lupus Erythematosus. PLoS One. 2016; 11(11):e0166202. PMC: 5106044. DOI: 10.1371/journal.pone.0166202. View

Beltrami C, Simpson K, Jesky M, Wonnacott A, Carrington C, Holmans P . Association of Elevated Urinary miR-126, miR-155, and miR-29b with Diabetic Kidney Disease. Am J Pathol. 2018; 188(9):1982-1992. DOI: 10.1016/j.ajpath.2018.06.006. View

Feng D, Wu B, Pang Y . Diagnostic value of urinary exosomal miR-23b-3p, miR-30a-5p, and miR-151-3p in children with primary nephrotic syndrome. Transl Androl Urol. 2020; 9(5):2235-2241. PMC: 7658171. DOI: 10.21037/tau-20-1260. View

Fouad M, Salem I, Elhefnawy K, Raafat N, Faisal A . MicroRNA-21 as an Early Marker of Nephropathy in Patients with Type 1 Diabetes. Indian J Nephrol. 2020; 30(1):21-25. PMC: 6977383. DOI: 10.4103/ijn.IJN_80_19. View

Naraba H, Iwai N . Assessment of the microRNA system in salt-sensitive hypertension. Hypertens Res. 2006; 28(10):819-26. DOI: 10.1291/hypres.28.819. View

10.

Huang Z, Shi J, Gao Y, Cui C, Zhang S, Li J . HMDD v3.0: a database for experimentally supported human microRNA-disease associations. Nucleic Acids Res. 2018; 47(D1):D1013-D1017. PMC: 6323994. DOI: 10.1093/nar/gky1010. View

11.

Harbord R, Deeks J, Egger M, Whiting P, Sterne J . A unification of models for meta-analysis of diagnostic accuracy studies. Biostatistics. 2006; 8(2):239-51. DOI: 10.1093/biostatistics/kxl004. View

12.

Zhao Y, Shen A, Guo F, Song Y, Jing N, Ding X . Urinary Exosomal MiRNA-4534 as a Novel Diagnostic Biomarker for Diabetic Kidney Disease. Front Endocrinol (Lausanne). 2020; 11:590. PMC: 7484971. DOI: 10.3389/fendo.2020.00590. View

13.

Abdul-Maksoud R, Rashad N, Elsayed W, Ali M, Kamal N, Zidan H . Circulating miR-181a and miR-223 expression with the potential value of biomarkers for the diagnosis of systemic lupus erythematosus and predicting lupus nephritis. J Gene Med. 2021; 23(5):e3326. DOI: 10.1002/jgm.3326. View

14.

Hu H, Wan Q, Li T, Qi D, Dong X, Xu Y . Circulating MiR-29a, Possible Use as a Biomarker for Monitoring IgA Nephropathy. Iran J Kidney Dis. 2020; 14(2):107-118. View

15.

Liu L, Chen H, Yun J, Song L, Ma X, Luo S . miRNA-483-5p Targets HDCA4 to Regulate Renal Tubular Damage in Diabetic Nephropathy. Horm Metab Res. 2021; 53(8):562-569. DOI: 10.1055/a-1480-7519. View

16.

Tayel S, Saleh A, El-Hefnawy S, Elzorkany K, Elgarawany G, Noreldin R . Simultaneous Assessment of MicroRNAs 126 and 192 in Diabetic Nephropathy Patients and the Relation of these MicroRNAs with Urinary Albumin. Curr Mol Med. 2019; 20(5):361-371. DOI: 10.2174/1566524019666191019103918. View

17.

Akpinar K, Aslan D, Fenkci S, Caner V . miR-21-3p and miR-192-5p in patients with type 2 diabetic nephropathy. Diagnosis (Berl). 2022; 9(4):499-507. DOI: 10.1515/dx-2022-0036. View

18.

Serino G, Pesce F, Sallustio F, De Palma G, Cox S, Curci C . In a retrospective international study, circulating miR-148b and let-7b were found to be serum markers for detecting primary IgA nephropathy. Kidney Int. 2015; 89(3):683-92. DOI: 10.1038/ki.2015.333. View

19.

Luo Y, Wang C, Chen X, Zhong T, Cai X, Chen S . Increased serum and urinary microRNAs in children with idiopathic nephrotic syndrome. Clin Chem. 2013; 59(4):658-66. DOI: 10.1373/clinchem.2012.195297. View

20.

Chung A, Huang X, Meng X, Lan H . miR-192 mediates TGF-beta/Smad3-driven renal fibrosis. J Am Soc Nephrol. 2010; 21(8):1317-25. PMC: 2938591. DOI: 10.1681/ASN.2010020134. View